Education Qualifications

• PGCHET (Postgraduate Certificate in Higher Education) 2005-2006, Queen’s University Belfast, UK
• PhD (Clinical Biochemistry) -  1994-1997 University of Liverpool, UK
• MPhil (Clinical Biochemistry) - 1992-1993 University of Liverpool, UK
• DSc’ (Clinical Biochemistry) – 1985-86, Alexandria University, Egypt
• BSc (Biochemistry) – 1977-81 Alexandria University, Egypt

Experience

Ras Khamah Medical and Health Sciences University (RAKMHSU), UAE 2023 - PRESENT        

• Vice president of Research and postgraduate affairs
• Dean of College of Pharmacy 

Al-ahliyya Amman University (AAU), Jordan 2019 - 2023

• Dean of Faculty of Pharmacy 
• Dean of Faculty of Allied Medical Sciences 
• Director of pharmacological and Diagnostic Research Centre (PDRC) 
• Director of audiology and speech pathology centres | Director of Arena Discovery for Pharmaceutical Industry and Research
• Proven ability to drive transformational change, enhance outreach and facilitate student success with the results I have achieved in my current role. I lead the faculties, to consistently achieving over 90% ultimate graduation rates, over 95% and 100% first-time pharmacy licensing board examination pass rates, nationally and internationally. Since my appointment, the total number of students enrolled in both faculties grew by an average of 20%.
• Leveraged networking skills to materialise my vision of a PDRC university-wide research centre and secured £4 million in funding for this new state of the art centre.
• Demonstrated ability to lead efforts to develop a strategy for university research priorities. As a result, I have increased externally funded research attracting from $150,000 in 2018 to more than $2,000,000 in 2021.
• My two faculties at AAU received complete Jordanian accreditation in 2021, and the Faculty of Pharmacy received full ACPE accreditation in 2022 by meeting all twenty-six requirements.

University of Bradford (UoB), UK 2014 – 2019

• Anniversary Chair (Professor) in Molecular Pathology and Cancer Therapeutics, School of Pharmacy and Medical Sciences, UoB 
• Deputy Director of Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, UoB
• Director of Collaborative Targeted Therapeutics & Diagnostics, School of Pharmacy and Medical Sciences, UoB
• Developed an extensive track record for developing a robust and mutually beneficial industry engagement program for research, technological innovation, and commercialization. As a result, I was the principal investigator on significant UK projects, including CRUK, Welcome Trust FP7 (£3.5 million), ITN Marie Curie (£3.5 million), Innovate UK – Biomedical Catalyst, a £2.0 million UK-China competition (SRISF). 
• Showed successful experience in progressively responsible research. For example, I lead a research team that used sophisticated techniques to produce targeted medicines (Ran inhibitors). Ran inhibitors have been found, including a monoclonal antibody, two repurposed medicines (MELT2014 and MELT2015), peptides, and a new small molecule that has been confirmed in in vivo preclinical tests. Moreover, during my appointment I secured 5 international medical patents including peptide and nanoparticle formulations, assays, and compounds for use in medicine.
• Made clear my experience with research administration and technology commercialization. Founding multiple successful spin-off companies, such as ARENA, Imhotep Diagnostics and Therapeutics (IDT), and Imhotep Diagnostics Health (IDX health).

Queens University Belfast (QUB), UK  2002 - 2014

• Professor in Molecular Oncology, School of Medical, Dentistry and Biomedical Sciences, QUB.       2012-2014
• Established an ability to merge research with industry successfully and grow a faculties research capability. For example, I lead QUB to the achievement of SPUR award, this granted the university’s cancer research centre a £15.8 million grant.
• Demonstrated ability to work with faculty, staff, and students as well as community groups of diverse backgrounds. Consequently, I collaboratively built the MSc degree programs in areas such as cancer pharmacology and digital pathology. What’s more I enhanced recruitment and retention of students by a significant proportion during my appointment.
• Developed excellent written and verbal communication skills and a strong professional network. Having published over 80 papers in high impact journals, serving as a senior editor and contributor to over 16 high-profile international journals and involvement in over 60 conferences worldwide.

OTHER ACADEMIC AND CLINICAL EMPLOYMENT HISTORY

• 2007-2012 Associate Professor in Molecular Oncology, School of Medical, Dentistry and Biomedical Sciences School, Queen's University Belfast (QUB)
• 2002-2007 Assistant Professor in Molecular Oncology, School of Medical, Dentistry and Biomedical Sciences School, Queen's University Belfast (QUB)
• 1997-2002 Postdoctoral Research Associate, School of Biological Sciences, University of Liverpool 
• 1994-1997 Research Associate, School of Biological Sciences, University of Liverpool 
• 1993-1994 Consultant Clinical Biochemist, Alexandria University Hospital, Egypt
• 1987-1992 Consultant Clinical Biochemist, King Khalid Hospital, Najran, Saudi Arabia
• 1981-1986 Clinical Biochemist, Alexandria University Hospital, Egypt

Courses Taught

• Advanced Clinical Biochemistry
• Clinical Biochemistry
• Advanced Molecular Diagnostics
• Molecular Technology/Biology
• Cancer Biology

Publications

PEER-REVIEWED PUBLISH PAPER

https://scholar.google.com/citations?view_op=list_works&hl=id&user=fiez7WAAAAAJ

Achievements

• Founder Pharmaceutical and Diagnostic Research Centre (PDRC) with over £4 million funding,
• Developed a new bachelor's degree program in Cosmetic Sciences at AAU in Jordan. The BSc in Cosmetic Sciences, AAU, is Jordan's first degree.
• Founded AAU's first master's degree in speech pathology.
• Founded first master's degree program in Medical Laboratory Sciences in the country's public and private universities. 
• Increased students enrolled in both my faculties at AAU grew by an average of 20%. (The number of failing students has dropped in both faculties since I was appointed).
• Recipient of a grant from the National Science Foundation's Scientific Research and Innovation Support Fund (SRISF). (This is the first time in the country that SRISF has awarded a grant to a private university).
• Established AAU's Institutional Review Board (IRB) for human and animal trials.
• Built a modern animal house at AAU and has been given GLP status by the Jordanian Food and Drug Administration.
• Principal investigator on significant UK projects, grossing over £20 million in funding.
• Published over 80 articles in prestigious publications.
• Leader of the team with the two repurposed medicines (MELT2014 and MELT2015), peptides, and a new small molecule that has been confirmed in in vivo preclinical tests.
• Team leader for the development of a Ran liquid test biomarker
• Founder of Imhotep Diagnostics and Therapeutics Ltd. (IDT) (www.imhotepdiagnosticsgroup.com), which now markets over 300 products and a revolutionary diagnostic biomarker in over 30 countries. 
• General director of Arena Ltd. (Jordan) for Pharmaceutical Industries and Research.
• Senior editor for numerous high-profile international publications 
• Contributor to various major national and international fund organizations as a reviewer